奈达铂联合紫杉醇新辅助化疗方案在局部晚期宫颈癌患者中应用分析.docVIP

奈达铂联合紫杉醇新辅助化疗方案在局部晚期宫颈癌患者中应用分析 　　[摘要]目的 探讨奈达铂联合紫杉醇新辅助化疗方案在局部晚期宫颈癌患者中的应用效果。方法 选取我院2014年1月～2017年2月收治的60例局部晚期宫颈癌患者，依据治疗措施不同分为A组和B组，各30例。A组采用紫杉醇治疗，B组采用奈达铂联合紫杉醇治疗。观察两组的临床疗效、治疗前后的生活质量（QOL）评分和Kamofsky评分情况，比较两组的不良反应情况。结果 B组的总缓解率为56.7%，高于A组的40.0%，差异有统计学意义（P0.05）。两组治疗后的QOL评分和Kamofsky评分均高于治疗前，B组治疗后的QOL评分和Kamofsky评分均高于A组，差异有统计学意义（P0.05）。B组的恶心呕吐发生率低于A组，差异有统计学意义（P0.05）。结论 奈达铂联合紫杉醇新辅助化疗方案在局部晚期宫颈癌患者中的应用效果显著，临床缓解率高，胃肠道反应发生率低，值得临床推广应用。 　　[关键词]奈达铂；紫杉醇；局部晚期宫颈癌 　　[中图分类号] R737.33 [文献标识码] A [文章编号] 1674-4721（2017）09（b）-0057-03 　　Application analysis of Nedaplatin combined with Paclitaxel as a new adjuvant chemotherapy regimen in patients with locally advanced cervical cancer 　　HAN Chun-ming 　　Department of Oncology，the Third People′s Hospital of Liaoyang City in Liaoning Province，Liaoyang 111000，China 　　[Abstract]Objective To investigate the application effect of Nedaplatin combined with Paclitaxel as a new adjuvant chemotherapy regimen in patients with locally advanced cervical cancer.Methods 60 patients with locally advanced cervical cancer admitted in our hospital from January 2014 to February 2017 were selected and divided into group A and group B according to different therapeutic measures，30 cases in each group.Group A was treated with Paclitaxel，and group B was given Nedaplatin combined with Paclitaxel treatment.The clicnial effect，score of quality of life （QOL） before and after therapy，and Kamofsky score in the two groups were observed.The adverse reaction was comapred in both groups.Results The total remission rate in group B was 56.7%，which was higher than 40.0% in group A，with significant difference （P0.05）.The QOL scores and Kamofsky scores of the two groups after treatment was higher than that before treatment， and the scores of QOL and Kamofsky scores in the group B after treatment was higher than that in group A，with significant difference （P0.05）.The incidence rate of nausea and vomiting in group B was lower than that in group A，with significant difference （P0.05）.C